In Silico Evaluation of Verbascoside Against Bromodomain and Breast Cancer–Associated Targets
In Silico Research in Biomedicine · 2026-11 · 100725
DOI: 10.1016/j.insi.2026.100725 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Silico Research in Biomedicine, 2026-11. Verfasst von Sweta Prasad und 2 weiteren Autor:innen. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
BRD4 drives oncogenic transcription in breast cancer by reading acetylated lysine. Verbascoside (acteoside), cytotoxic to breast cancer cells at micromolar concentrations, has no known target. We asked whether validated docking supports BRD4 as a testable hypothesis.
Methods
Verbascoside, its regioisomer isoacteoside, the BET probe (+)-JQ1, and unrelated comparators paclitaxel and methotrexate were docked (AutoDock Vina 1.2.5, five seeds) against seven structures: BRD1–BRD4, BRCA1, PALB2 and BCAR3. Validity was tested by redocking co-crystallised ligands; BRD4 complexes were simulated in triplicate for 100 ns.
Results
Verbascoside scored well (−7.9 to −10.5 kcal/mol), matching (+)-JQ1 at BRD4 (−8.2 versus −8.4 kcal/mol). Yet paclitaxel, without BET activity, outscored every compound at all seven: the ranking is size-driven. Redocking reproduced the crystallographic pose only with pocket waters retained (1.72 versus 5.02 Å). There (+)-JQ1 settled into one pose in all five seeds, hydrogen-bonding N140 and engaging the complete WPF shelf; verbascoside into none, reaching N140 only at 3.73–3.78 Å, while a pose 6.0 Å away scored within 0.05 kcal/mol. In simulation (+)-JQ1 stayed in the pocket (N140 occupancy 86.4%); verbascoside left in two of three replicas (13.8%).
Conclusions
A favourable score is not engagement. Verbascoside does not reproduce canonical BET recognition, and its ∼117 µM cytotoxicity lies three orders of magnitude above JQ1’s nanomolar potency — different endpoints, not directly equivalent, but a gap that size argues against BET inhibition as the principal mechanism. It is a computationally evaluated scaffold whose direct BRD4 binding remains unconfirmed and requires experimental testing, not an established lead.
Zitieren
APA
Prasad, S., Ghosh, A., & Sarkar, A. (2026). In Silico Evaluation of Verbascoside Against Bromodomain and Breast Cancer–Associated Targets. In Silico Research in Biomedicine, 100725. https://doi.org/10.1016/j.insi.2026.100725
Vancouver
Prasad S, Ghosh A, Sarkar A. In Silico Evaluation of Verbascoside Against Bromodomain and Breast Cancer–Associated Targets. In Silico Research in Biomedicine. 2026:100725. doi:10.1016/j.insi.2026.100725
BibTeX
@article{Prasad2026,
author = {Prasad, Sweta and Ghosh, Arijit and Sarkar, Agniswar},
title = {In Silico Evaluation of Verbascoside Against Bromodomain and Breast Cancer–Associated Targets},
journal = {In Silico Research in Biomedicine},
year = {2026},
pages = {100725},
doi = {10.1016/j.insi.2026.100725}
}
EUVIMED